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Introduction: Hyperprolactinaemia, a common adverse effect of antipsychotic drugs, is
primarily linked to blockade of dopamine D2 receptors in the pituitary gland. Certain
antipsychotic drugs, such as, for example risperidone and paliperidone, are more likely
to induce hyperprolactinaemia compared to others. This effect is probably caused by a
relatively high blood/brain concentration ratio, a consequence of being a substrate of
P-glycoprotein. Genetic variants of P-glycoprotein with changed functional activity
might influence the potential of risperidone and paliperidone to cause hyper-
prolactinaemia as the altered blood/brain concentration ratio would lead to a reduced
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therapeutic drug level within essential brain areas making dose adaptations necessary.
This increases exposure of dopamine D2 receptors within the pituitary gland.
Aims: To investigate possible associations between MDR1/ABCB1 gene polymor-
phisms and antipsychotic drug-induced hyperprolactinaemia in Russian patients with
schizophrenia and to determine possible differences between risperidone/
paliperidone and other antipsychotics.
Methods: In total, 446 patients with schizophrenia were included from 3 psychiatric
hospitals in Siberia. Blood samples were obtained in a cross-sectional study design
for DNA extraction and prolactin measurement. Associations between hyper-
prolactinaemia and 8 MDR1/ABCB1 gene-polymorphisms were assessed using logistic
regression analysis accounting for covariates. The analysis was repeated in a patient
subgroup using risperidone or paliperidone.
Results: We did not observe an association between any of the 8 single nucleotide
polymorphisms and the prevalence of antipsychotic-induced hyperprolactinaemia in
the total patient population. However, in the risperidone/paliperidone subgroup, the
single nucleotide polymorphism rs2032582 (G2677T) was found to be negatively
associated with risperidone/paliperidone-induced hyperprolactinaemia.
Conclusion: This study revealed a significant association between the ABCB1 gene
polymorphism rs2032582 (G2677T) and risperidone/paliperidone-induced
hyperprolactinaemia.
K E YWORD S
antipsychotics, hyperprolactinaemia, MDR1/ABCB1 gene, P-glycoprotein, polymorphisms
1 | INTRODUCTION
Prolactin is a polypeptide hormone that is excreted into the blood by
lactotroph cells of the anterior pituitary gland. Increased excretion of
this hormone causes hyperprolactinaemia (HPRL), a common side
effect of both classical and atypical antipsychotic drugs. HPRL is char-
acterized by both acute and chronic consequences such as sexual
impairment, hypogonadism, galactorrhoea, amenorrhoea, reproductive
dysfunctions, weight gain, osteoporosis, cardiovascular disease and
depression.1–5
Even though almost all antipsychotic drugs can cause HPRL, the
highest rates of HPRL are commonly associated with the use of ami-
sulpride, risperidone or paliperidone.6 The occurrence of antipsychotic
drug-induced HPRL is attributed to blockade of the dopamine
D2-receptors on the membranes of lactotroph cells within the pitui-
tary gland. A higher occupancy rate of the D2-receptors seems to give
a greater chance of developing HPRL. The threshold of D2-receptor
occupancy for the development of HPRL might differ among antipsy-
chotic drugs, but a minimum of 72% D2-receptor occupancy seems
necessary.6–8
Since pituitary D2-receptor occupation seems important for
developing HPRL, the penetration potency of an antipsychotic drug
across the blood–brain barrier (BBB) might influence its occurrence.6
The pituitary gland is anatomically not protected by the BBB.9 The
less an antipsychotic drug is capable to penetrate the BBB, the higher
the concentration within the pituitary gland will be in order to reach a
therapeutic drug level within essential brain areas. A higher drug con-
centration at the pituitary might result in a higher amount of
What is already known about this subject
• Hyperprolactinaemia is attributed to blockade of dopa-
mine D2 receptors on the membranes of lactotroph cells
within the pituitary gland
• Certain antipsychotic drugs, e.g. risperidone and
paliperidone, are more likely to induce hyper-
prolactinaemia compared to others.
• The strong prolactin-elevating effect of risperidone is prob-
ably caused by a relatively high blood/brain concentration
ratio, a consequence of being a substrate of P-glycoprotein.
What this study adds
• Genetic variations in the MDR1/ABCB1 gene, such as
rs2032582 (G2677T), might influence the occurrence of
risperidone/paliperidone induced hyperprolactinaemia
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D2-receptor occupation and thus in an increased risk of HPRL.6,10
The relatively high blood/brain concentration ratio of risperidone,
partly caused by its high affinity for the P-glycoprotein (P-gp) efflux
transporter3,11 for example, may well be the origin of its common
prolactin-elevating effect.
The P-gp efflux transporter, encoded by the ATP binding cassette
subfamily B member 1 (ABCB1) gene also known as multidrug resistance
gene 1 (MDR1), is a transmembrane protein expressed at the BBB. It
transports penetrated chemicals back from the brain into the blood-
stream.12,13 Several antipsychotic drugs are known to have more or less
affinity for the P-gp transporter. Quetiapine and risperidone for exam-
ple are relatively good substrates of P-gp. Clozapine and haloperidol on
the other hand seem to have less affinity for the P-gp transporter.14
Genetic variations in the ABCB1 gene may cause differences in the
expression level and/or the functionality of the P-gp transporter.15,16
More than 50 single nucleotide polymorphisms (SNPs) in the ABCB1
gene are currently known, of which at least 28 are at positions that can
possibly influence the efficacy of the P-gp transporter.17,18
P-gp transporter proteins with alternative functional activity by
genetic variations might influence the potential of antipsychotic drugs
to cause HPRL. When the functionality of the P-pg transporter is
reduced, the blood/brain ratio of substrate antipsychotic drugs will
also be reduced. This results in a potentially higher penetration of
antipsychotics into the brain at a normal dosage level, which increases
the vulnerability for central nervous system side effects such as par-
kinsonism. Such central nervous system side effects can be expected
to result in dosage adaptations, causing a lower drug concentration
within the pituitary gland. This leads to a decrease in exposure and
occupancy of the lactotroph dopamine D2 receptor by this antipsy-
chotic drug. As a result, the chance of developing antipsychotic-
induced HPRL will also decrease.
To investigate the above theory, we studied the influence of
8 polymorphisms in the ABCB1 gene on the prevalence of
antipsychotic-induced HPRL in patients with schizophrenia and tried
to determine possible differences between risperidone/paliperidone
on the one hand and other antipsychotics on the other.
2 | METHODS
2.1 | Patients
For this study, 446 patients were included from psychiatric hospitals
in Kemerovo, Tomsk and Chita oblasts in Siberia, Russian Federation.
The study group and used methods are previously described by
Ivanova et al.19,20 Patients were included if they were diagnosed
with schizophrenia according to ICD-10 (F20), were using antipsy-
chotic drugs for a sufficiently long period and were between 18 and
75 years old. Exclusion criteria were pregnancy, non-Caucasian eth-
nicity, self-reported or by observed physical appearance, organic
brain disorders (Parkinson's disease, epilepsy), relevant thyroid or
gynaecological disorders, or pharmacological withdrawal symptoms.
Patients were treated for their schizophrenic disorder with
conventional and/or atypical antipsychotic drugs in both oral and
long-acting formulations. Haloperidol was the most commonly used
conventional antipsychotic drug. Other conventional antipsychotics
included oral chlorpromazine, chlorprothixene, trifluoperazin and
zuclopentixol, and long-acting formulations of haloperidol,
zuclopentixol and flupentixol. Atypical antipsychotics were used by
176 patients and included paliperidone, risperidone, amisulpride, clo-
zapine, olanzapine, sertindole and quetiapine. A total of 79 patients
used various combinations of classical and atypical drugs. All dosages
are recalculated into chlorpromazine equivalents (CPZeq) to compare
the antipsychotic exposure.21
The study procedures were accepted by the Local Bioethics Com-
mittee of the Mental Health Research Institute (Tomsk). The study
was recorded under protocol number N63/7.2014. Patients were
included after providing written informed consent. All work was per-
formed in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki 1975, revised in Fortaleza, Brazil,
2013) for experiments involving humans.
2.2 | Sampling
Blood samples for DNA extraction and prolactin measurement were
obtained after 8 hours of overnight fasting before intake of any
food or medication in a cross-sectional study design. For
premenopausal women, samples were preferably collected in the
follicular phase of the menstrual period. EDTA tubes were used for
collecting the blood samples for DNA extraction. The tubes were
stored at –20C until DNA isolation. Tubes with CAT (clot activa-
tor) were used to collect serum for measuring prolactin concentra-
tions (BD Vacutainer). The samples were centrifuged for
30 minutes at 200x g at 4C to obtain serum.
2.3 | Biochemical analysis
2.3.1 | Prolactin concentration
The prolactin concentration was determined using an accuBind
enzyme-linked immunosorbent assay Microwells kit (Monobind Inc.,
USA). The sensitivity of the kit was 0.004 ng/well, which is equal
to a prolactin concentration of 0.150 ng/mL. The upper limit for a
normal prolactin concentration was fixed at ≤25 ng/mL for non-
pregnant, non-nursing women and at ≤20 ng/mL for men. These
criteria for HPRL were confirmed in literature.6,22
2.3.2 | DNA analysis
For this study, 8 SNPs in the ABCB1 gene were selected based on
a literature search for relevant polymorphic variants of the gene in
patients with schizophrenia: rs1045642 (C3435T), rs2032582
(G2677T), rs4148739, rs28401781, rs2235040, rs9282564,
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rs2235015, and rs2032583.15,23–29 SNPs were selected based on the
relevance of the selected SNPs to associations with schizophrenia,
drug-induced side effects or treatment response. The minor allele
frequency of selected SNPs should have been 0.05 (5%) or greater.
A standard phenol–chloroform micro method (as described by
Ivanova et al.)30 was used to isolate DNA from the leucocytes in the
whole peripheral blood samples. Genotyping was performed with a
MassARRAY system 4 (Agena Bioscience) in the Genome Analysis
Facility, Department Genetics of the University Medical Center
Groningen.
2.4 | Statistics
Associations between the presence of HPRL in patients and the
variant of the ABCB1 gene were assessed using logistic regression
analysis accounting for covariates (sex, age, duration of the disease,
smoking, leading symptoms [positive/negative] and drug dosage
[CPZeq]). The analyses were carried out both in the total sample of
patients and in a subgroup characterized by the use of
risperidone/paliperidone, based on the strong affinity of risperidone
and its major metabolite for the P-gp transporter and their common
prolactin-elevating effect (n = 76). Sulpiride and amisulpride are also
consistently reported to cause HPRL however, their sample size was
insufficient for a proper subanalysis (n = 13). ABCB1 haplotypes were
not analysed since the statistical power of such an analysis is limited
caused by the low incidence rate of the recessive genotype/allele
which we observed.
The statistical program R with basic R functions and the
SNPassoc package v.3.1.331 was used for all statistical analyses.
P-values <.05 were considered significant. Bonferroni correction
was applied assuming 5 independent tests. The number of indepen-
dent tests was estimated based on the correlation between the
8 SNPs.
The deviation from Hardy–Weinberg equilibrium was tested with
χ2 test.
2.5 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
TABLE 1 Patient characteristics of the total population
Trait Total sample Men Women
n 446 221 (49.6%) 225 (50.4%)
Age (y)
Mean ± SD 41.5 ± 13.4 37.8 ± 11.9 45.2 ± 13.9
Median 40 36 44
Daily dose in CPZeq
Median 425 500 372
Duration of disease (y)
Mean ± SD 15.4 ± 11.5 13.1 ± 10.0 17.6 ± 12.5
Median 13 11 15
Type of therapy
Conventional antipsychotics 191 (42.8%) 91 (41.2%) 100 (44.4%)
Atypical antipsychotics 176 (39.5%) 78 (35.3%) 98 (43.6%)
Combination therapy 79 (17.7%) 52 (23.5%) 27 (12.0%)
Smoking (+/−/?) 259 (58.1%) /179 (40.1%) /8 (1.8%) 173 (78.3%) /46 (20.8%) /2 (0.9%) 86 (38.2%) /133 (59.1%) /6 (2.7%)
Hyperprolactinaemia (+/−) 227 (50.9%) /219 (49.1%) 98 (44.3%) /123 (55.7%) 129 (56.9%) /96 (42.7%)
Prolactin (ng/mL) total
Mean ± SD 34.7 ± 29.5 25.7 ± 22.5 43.5 ± 32.8
Range 1.5–140.6 1.5–122.1 2.1–140.6
Prolactin (ng/mL; HPRL+)
Mean ± SD 55.9 ± 27.5 43.5 ± 23.2 65.3 ± 26.9
Range 20.2–140.6 20.2–122.1 25.1–140.6
Prolactin (ng/mL; HPLR–)
Mean ± SD 12.6 ± 5.8 11.5 ± 5.0 14.1 ± 6.4
Range 1.5–24.9 1.5–20.0 2.1–24.9
CPZeq, chlorpromazine equivalents; HPRL, hyperprolactinaemia.
1830 GEERS ET AL.




A total of 446 patients from Siberia (225 female/221 male) partici-
pated in this study.19 The general characteristics of the population are
presented in Table 1. The median dosage of antipsychotic drugs was
425 CPZeq daily and the mean age of the patients was 41.5 years
(SD ± 13.4). The mean duration of schizophrenia was 15 years. Of
these, 191 patients were treated with conventional antipsychotics
(42.8%), 176 with atypical antipsychotics (39.5%), and 79 with a com-
bination of conventional and atypical antipsychotics (17.7%). Based
on the established lower limit for the presence of HPRL at >25 ng/mL
for females and >20 ng/mL for males, 227 of the 446 patients were
classified as HPRL positive.6,22 The mean prolactin concentration in
the total population was 34.7 ng/mL. The mean prolactin concentra-
tion in the HPLR positive and negative group was 55.9 and
12.6 ng/mL, respectively. Female patients had a higher mean prolactin
concentration compared to male patients.
3.2 | Patients using risperidone/paliperidone
Seventy-six patients (45 female/31 male) were included in the
risperidone/paliperidone subgroup. The baseline characteristics of this
subgroup are presented inTable 2. The current median dosage of anti-
psychotic drugs was 300 CPZeq daily. The mean age of the patients
was 38.1 years and patients suffered in general about 12.5 years of
schizophrenia. Sixty-six patients were treated with risperidone or
paliperidone only (86.8%) and 10 with a combination of these with
conventional antipsychotics (13.2%). Based on the established lower
limit for the presence of HPRL at >25 ng/mL for females
and >20 ng/mL for males, 59 of the patients were classified as HPRL
positive.6,22 The mean prolactin concentration in the
risperidone/paliperidone population was 53.0 ng/mL. The mean pro-
lactin concentration in the HPLR positive and negative group were
64.9 and 11.9 ng/mL, respectively. Female patients had a higher mean
prolactin concentration in this group compared to male patients.
3.3 | Logistic regression model
The association between the SNPs and the occurrence of HPRL was
assessed using logistic regression with adjustment for covariates (sex,
TABLE 2 Patient characteristics of the patients in the risperidone/paliperidone subgroup
Trait Total sample Men Women
n 76 31 (40.8%) 45 (59.2%)
Age (y)
Mean ± SD 38.1 ± 14.1 33.1 ± 11.5 41.6 ± 14.8
Median 34 31 40
Daily dose in CPZeq
Median 300 396 200
Duration of disease (y)
Mean ± SD 12.5 ± 12.3 9.6 ± 10.0 14.5 ± 13.4
Median 10.0 6.5 11.0
Type of therapy
Atypical antipsychotics 66 (86.8%) 25 (80.6%) 41 (91.1%)
Combination therapy 10 (13.2%) 6 (19.4%) 4 (8.9%)
Smoking (+/−/?) 31 (40.8%) /43 (56.6%) /2 (2.6%) 21 (67.7%) /10 (32.3%) /0 10 (22.2%) /33 (73.3%) /2 (4.5%)
Hyperprolactinaemia (+/−) 59 (77.6%)/17(22.4%) 20 (64.5%)/11 (35.5%) 39 (86.6%) /6 (13.3%)
Prolactin (ng/mL) total
Mean ± SD 53.0 ± 34.4 35.8 ± 29.3 64.9 ± 32.9
Range 4.6–124.0 4.6–122.1 6.4–124.0
Prolactin (ng/mL; HPRL+)
Mean ± SD 64.9 ± 29.7 49.2 ± 28.5 72.9 ± 27.4
Range 20.2–124.0 20.2–122.1 28.1–124.0
Prolactin (ng/mL; HPRL–)
Mean ± SD 11.9 ± 4.8 11.6 ± 5.6 12.5 ± 3.5
Range 4.6–19.1 4.6–19.1 6.3–16.5
CPZeq, chlorpromazine equivalents; HPRL, hyperprolactinaemia.
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age, smoking, duration of the disease, leading symptoms [positive/
negative] and drug dosage [CPZeq]). The genotypes prevalence for all
SNPs was in consistency with Hardy–Weinberg equilibrium. Sex and
age had a significant relation with the occurrence of HPRL (P = .032
and P = .031 respectively).
A nominally significant association between 2 SNPs in the P-gp
gene (rs1045642 [C3435T] and rs4148739) and HPRL was
established (Table 3). However, after Bonferroni correction for multi-
ple testing, both associations were no longer significant (Figure 1).
In the risperidone/paliperidone subgroup, the results of the logis-
tic regression analysis showed also a significant association between
2 SNPs and the occurrence of HPRL (rs1045642 [C3435T] and
rs2032582 [G2677T]; Table 4). After correction for multiple testing,
the SNP rs2032582 (G2677T) was still significantly associated with
the occurrence of HPRL (Figure 1).
4 | DISCUSSION
In this study, the association between 8 polymorphisms in the ABCB1
gene and antipsychotic drug-induced HPRL was investigated in
Russian patients with schizophrenia from Siberia. No association was
found between any SNP and the prevalence of antipsychotic drug-
induced HPRL in the total group of patients with schizophrenia. How-
ever, the rs2032582 (G2677T) variant was found to be negatively
associated with risperidone/paliperidone-induced HPRL.
In this study, the prolactin level and occurrence of HPRL was
determined in a large number of patients. Normal serum concentra-
tions of prolactin can be affected by several factors such as sex,
circadian variations, the menstrual cycle and menopause. Also,
heavy meals, exercise, sexual intercourse, pregnancy, breastfeeding
and epileptic seizures are known to increase the serum prolactin
level.6,23
In our study, patients with various physical and/or psychological
disorders that can affect the serum prolactin level were excluded. We
also corrected for sex differences by the use of different lower limits
for HPRL for men and women. Also, all samples were obtained after
TABLE 3 Result logistic regression analysis between
polymorphisms in the P-glycoprotein transporter gene and
hyperprolactinaemia in patients with schizophrenia
SNP OR 95% CI Raw P-value
rs1045642 1.365 1.011–1.842 .048
rs2032582 0.813 0.606–1.091 .173
rs4148739 1.581 0.953–2.621 .034
rs28401781 1.517 0.931–2.472 .084
rs2235040 1.448 0.878–2.386 .128
rs9282564 0.850 0.550–1.314 .554
rs2235015 1.388 0.916–2.103 .147
rs2032583 1.603 0.980–2.622 .052
CI, confidence interval; OR, odds ratio; SNP, single nucleotide
polymorphism.
F IGURE 1 A, The –log10 P-values of the association between
polymorphisms in the P- glycoprotein receptor gene and
hyperprolactinaemia in patients with schizophrenia. B, The –log10
P-values of the association between polymorphisms in the P-
glycoprotein receptor gene and hyperprolactinaemia in patients with
schizophrenia using risperidone or paliperidone
TABLE 4 Result logistic regression analysis between
polymorphisms in the P-glycoprotein transporter gene and
hyperprolactinaemia in patients with schizophrenia using risperidone
or paliperidone
SNP OR 95% CI Raw P-value
rs1045642 3.103 0.729–13.21 .039
rs2032582 0.165 0.035–0.790 .008
rs4148739 3.086 0.297–32.05 .231
rs28401781 2.567 0.255–25.89 .369
rs2235040 2.148 0.209–22.12 .428
rs9282564 0.270 0.052–1.407 .267
rs2235015 4.406 0.719–26.99 .105
rs2032583 2.567 0.255–25.89 .369
CI, confidence interval; OR, odds ratio; SNP, single nucleotide
polymorphism.
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8 hours of overnight fasting, before intake of any food or medication,
to reduce the influence of meals, exercise and circadian influences on
the prolactin level.
The time between drug intake and sampling was pretty much ran-
dom. The overnight fasting period, however, ensures that all samples
were taken at least 8 hours after drug intake. The within-day plasma
level fluctuations of pituitary dopamine D2 occupancy are also
assumed to be small when antipsychotics are taken chronically in a
stable dosage. Lack of relationship between drug intake and prolactin
levels was e.g. confirmed in schizophrenic patients using risperidone
for at least 4 weeks by Yasui-Furukori et al.32
Despite the large number of patients and the accurate sampling
procedure, our study has several limitations. For example, no distinc-
tion was made between pre- and postmenopausal woman and the
phase of the menstrual cycle was not taken in account. For
premenopausal women, samples were preferably collected in the fol-
licular phase of the menstrual period. However, many women with
schizophrenia do not have spontaneous periods caused by
amenorrhoea, often a consequence of either psychosis and/or HPRL.
Also, a fixed lower limit was used for the occurrence of HPRL. This
lower limit was, however, accurately determined according to litera-
ture data. Also varying the lower limit during the statistical analysis did
not to affect the outcome.
Furthermore, we did not measure serum concentrations of the
antipsychotic drugs, so noncompliance could not be discovered.
Patients were, however, titrated with the antipsychotic drug to opti-
mal effect.
There is also no reason to assume that other factors that might
influence the plasma level, such as noncompliance or CYP enzyme
activity differences, are not randomly distributed between the differ-
ent genotypes we studied, since the number of patients included in
the study is sufficiently high.
In this study, we focused on the influence of 8 SNPs on the func-
tionality and effectiveness of the P-gp transporter present in the BBB.
P-gp transporters are, however, also present in various organs with a
barrier or excretory function including the small intestine, lungs, liver
and kidneys.33,34 Therefore HPRL is not strictly related to the influ-
ence of a polymorphism of the ABCB1 gene on the functioning of the
BBB as the blood/brain ratio is also affected by the functionality of P-
gp in various organs with a barrier or excretory function which might
influence the antipsychotic blood concentration. Several studies
attempted to find a relation between SNPs in the ABCB1 gene and
pharmacokinetics of antipsychotic drugs but so far the results are
inconsistent and sometimes conflicting.35–38
The patients included in our study were using different types of
antipsychotics. Since there are major differences between antipsy-
chotics according to their affinity for the P-gp transporter, the associ-
ation between P-gp gene polymorphisms and the occurrence of
HPRL might also differ between antipsychotic drugs. To correct for
this difference, an additive genetic model was tested, and the analy-
sis was carried out both in the total sample of patients and in a sub-
group characterized by the usage of risperidone/paliperidone
(n = 76). In the risperidone/paliperidone subgroup, a negative
association between the rs2032582 (G2677T) variant with
risperidone/paliperidone-induced HPRL was observed. In the total
population, the association was also significant but did not survive
correction for multiple testing.
The SNP rs2032582 (c.2677 T/A/G) polymorphism of the P-gp
gene is a nonsynonymous missense mutation in exon 21 that results
in the substitution of alanine to threonine or serine. The c.2677 T/G
polymorphism (p.Ala893Ser) is the most common SNP in human,
while the 2677G/A (Ala893Thr) polymorphism is less often
observed.12 In our research, we analysed the (2677 T/G) variant.
The mechanism of the influence of the rs2032582 (G2677T)
polymorphism on the concentration and function of the P-pg
transporter protein is unclear. Several studies reported no difference
in P-gp expression between carriers of various rs2032582
genotypes,39–41 but a few report a significant reduction of the P-gp
gene expression and/or protein function in carriers of the variant
allele.42,43 The results of our study suggest that the rs2032582
polymorphism might alter the function of the P-gp transporter within
the BBB. However, it is also possible that the polymorphism is linked
to another SNP that actually influences the efficacy of the P-gp
transporter.
There was no association found between the other tested poly-
morphisms of the P-gp gene and the prevalence of antipsychotic-
induced HPRL in both the entire study population as in the
risperidone/paliperidone subgroup. Unfortunately, from almost all
SNPs in the P-gp gene, it is unclear to what extent they actually influ-
ence the functionality and effectiveness of the P-gp transporter. Also,
most of the examined SNPs are located at intron regions and there-
fore might not directly influence the functionality of the P-gp
transporter.
In conclusion, no association was found between any of the
8 SNPs and antipsychotic drug-induced HPRL. However, the
rs2032582 (G2677T) variant appeared to be protective against
HPRL in the subgroup of patients using risperidone or paliperidone.
Further research to the influence of polymorphisms in the P-gp
gene on the functionality and efficacy of the P-gp transporter and
the related influence on the plasma levels of several antipsychotic
drugs is eligible.
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